Drug updated on 11/15/2023
|Tablet (oral; 200 mg)
|Ongoing and Completed Studies
- For the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Product Monograph / Prescribing Information
|Tazverik (tazemetostat) Prescribing Information.
|Epizyme Inc., Cambridge, MA